GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2011

Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate

  • Lonza is to provide Genmab with development and cGMP manufacturing expertise for the latter’s preclinical-stage anticancer antibody-drug conjugate (ADC) candidate targeting tissue factor (TF). Under terms of the deal Lonza will carry out process development and cGMP manufacturing for Genmab’s fully human HuMax-TF™ antibody, which is expressed in Lonza’s GS Gene Expression System. Lonza will then conjugate the naked antibody at its ADC plant to generate the final antibody-drug conjugate.

    The HuMax-TF ADC is currently undergoing preclinical development in collaboration with Seattle Genetics, which has provided the ADC technology. Under terms of the deal Seattle retains opt-in rights to the anti-TF ADC, and also an anti-CD74 ADC program, at completion of Phase I clinical trials. 

    Seattle’s technology combines highly potent cell-killing auristatins, with stable linkers that attach the cytotoxic drug to the antibody. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?